GlassScriptPhysician profile
Jeffrey J Glass
NPI 1760443261
$6,759.07
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,857 · 2020: $1,864 · 2021: $1,817 · 2022: $953 · 2023: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $250 · Education: $16.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $250.48 |
| Education | $16.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $1,023.07 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $968.07 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $638.29 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $390.68 | 2019-2023 | Entyvio |
| Kowa Pharmaceuticals America, INC. | $374.16 | 2020-2023 | Seglentis |
| Lilly USA, LLC | $343.76 | 2019-2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $333.09 | 2019-2021 | |
| Abbvie INC. | $316.58 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $309.87 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.29 | 2019-2023 | |
| Ucb, INC. | $196.39 | 2019-2020 | |
| Ibsa Pharma INC. | $165.10 | 2019-2022 | |
| Amgen INC. | $146.09 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $120.69 | 2019-2021 | |
| Esperion Therapeutics, INC. | $119.29 | 2020-2023 | Nexletol |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Glass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.